Intas Pharmaceuticals has filed a draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) and the stock exchanges for an initial public offering (IPO). The IPO will be made through a public issue of equity shares of face value of Rs 10 each (equity shares) including a share premium, which will be determined on a later date, aggregating Rs 2,250 million (fresh issue) and an offer for sale of 11,621,100 equity shares by Mozart (the ‘Offer for Sale’ and together with the Fresh Issue, the ‘Issue’).
The issue is being made through the book building process, wherein not more than 50 per cent of the issue shall be allocated on a proportionate basis to qualified institutional buyers (as defined in the SEBI (issue of capital and disclosure requirements), Regulations, 2009, as amended. The company may, in consultation with the book running lead managers, allocate up to 30 per cent of the QIB Portion to anchor investors at the anchor investor allocation price, on a discretionary basis, out of which at least one-third will be available for allocation to domestic mutual funds only.
The promoters of the company are Hasmukh Chudgar, Binish Hasmukh Chudgar, Nimish Hasmukhbhai Chudgar, Dr Urmish Hasmukh Chudgar, Kusum Chudgar, Bina Chudgar, Bindi Chudgar, Parul Chudgar, Shail Chudgar, Intas Enterprise, Equatorial, and Cytas Research.
Kotak Mahindra Capital Company and Morgan Stanley India Company are the book running lead managers to the issue and Link Intime India is the registrar to the issue.
EP News Bureau – Mumbai